Alvotech/$ALVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
Ticker
$ALVO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Luxembourg, Luxembourg
Employees
1,012
ISIN
LU2458332611
Website
Alvotech Metrics
BasicAdvanced
$2.8B
27.20
$0.34
0.19
-
Price and volume
Market cap
$2.8B
Beta
0.19
52-week high
$13.81
52-week low
$7.35
Average daily volume
264K
Financial strength
Current ratio
1.726
Quick ratio
1.006
Long term debt to equity
-391.392
Total debt to equity
-405.888
Interest coverage (TTM)
0.85%
Profitability
EBITDA (TTM)
147.647
Gross margin (TTM)
60.74%
Net profit margin (TTM)
16.42%
Operating margin (TTM)
22.02%
Effective tax rate (TTM)
4.43%
Revenue per employee (TTM)
$580,000
Management effectiveness
Return on assets (TTM)
7.02%
Return on equity (TTM)
-20.09%
Valuation
Price to earnings (TTM)
27.201
Price to revenue (TTM)
4.341
Price to book
-8.58
Price to tangible book (TTM)
-7.74
Price to free cash flow (TTM)
-11.36
Free cash flow yield (TTM)
-8.80%
Free cash flow per share (TTM)
-81.16%
Growth
Revenue change (TTM)
413.92%
Earnings per share change (TTM)
-115.98%
3-year revenue growth (CAGR)
146.40%
3-year earnings per share growth (CAGR)
2.20%
Bulls say / Bears say
Alvotech reported a substantial revenue increase in Q4 2024, with total revenues reaching $492 million, marking a 400% growth compared to the previous year. (Investing.com)
The company has been added to the Nasdaq Biotechnology Index, enhancing its visibility and potentially attracting more investors. (TipRanks)
Alvotech announced the U.S. availability of SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara®, expanding its product portfolio and market reach. (StockTitan)
Alvotech's stock hit a 52-week low at $8.88 amid market challenges, reflecting investor concerns. (Investing.com)
The company reported an earnings per share (EPS) loss of $0.22 in Q4 2024, falling short of the projected EPS gain of $0.01. (Investing.com)
Alvotech saw a significant increase in short interest, with shares sold short rising by 48.8% in December 2024, indicating bearish sentiment among investors. (ETF Daily News)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
Alvotech News
AllArticlesVideos
Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors
GlobeNewsWire·7 days ago
Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors
GlobeNewsWire·7 days ago
Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alvotech stock?
Alvotech (ALVO) has a market cap of $2.8B as of June 18, 2025.
What is the P/E ratio for Alvotech stock?
The price to earnings (P/E) ratio for Alvotech (ALVO) stock is 27.2 as of June 18, 2025.
Does Alvotech stock pay dividends?
No, Alvotech (ALVO) stock does not pay dividends to its shareholders as of June 18, 2025.
When is the next Alvotech dividend payment date?
Alvotech (ALVO) stock does not pay dividends to its shareholders.
What is the beta indicator for Alvotech?
Alvotech (ALVO) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.